The Food and Drug Administration (FDA) gave clearance to the first interventional device (RIST Cath Radial Access Long Sheath; RIST Neurovascular, Miami Beach, FL) designed to access the peripheral, coronary, and neurovascular systems through the radial artery in the wrist.
The device enables several neurovascular procedures to be performed transradially. Cardiology studies have shown a significant reduction in access site complications as well as mortality with radial access (NCT04077762). Also, radial access procedures offer several other advantages, such as strong individual preference, immediate ambulation, and reduced costs.
“Although transradial techniques have become the standard of care in the cardiac interventional communities, neurointerventionalists have not previously had the appropriate tools to allow these advantages for patients undergoing neurovascular procedures,” said Pascal M. Jabbour, MD, professor of neurological surgery and chief of the division of neurovascular and endovascular neurosurgery, Thomas Jefferson University. “Clearance of the RIST Cath provides neuroendovascular specialists a safe and durable tool to perform neuroendovascular interventions via a transradial approach and allows us to offer improved care for patients while pushing the envelope of what our field has to offer.”
James Geyer, MD; and Jenna Cooper, CRNP
Michael V. Robers, MD; Deepak Soneji, MD, PhD; and Lilyana Amezcua, MD, MS
Adil Javed, MD, PhD; and James Stankiewicz MD, FAAN